Hepatitis vaccines

British Medical Bulletin

Volumn 70, Issue , 2004, Pages 29-49

  Karayiannis, Peter ^a   Main, Janice ^a   Thomas, Howard C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; DNA VACCINE; FORMALDEHYDE; GENE PRODUCT; GLYCOPROTEIN E; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HEPATITIS D VACCINE; HEPATITIS E VACCINE; HEPATITIS VACCINE; HUMAN NORMAL IMMUNOGLOBULIN; IMMUNOGLOBULIN; INFLUENZA VIRUS HEMAGGLUTININ; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; OPEN READING FRAME 2 PROTEIN; OPEN READING FRAME 3 PROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PROTEIN VACCINE; RECOMBINANT HEPATITIS B VACCINE; SIALIDASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEPATITIS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E VIRUS; HUMAN; INJECTION PAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION;

HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS E; HUMANS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

EID: 8544276345     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/ldh024     Document Type: Review

References (164)

1. Stokes JJ, Neefe JR (1945) The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA, 127, 144-145.
2. Hadler SC, Erben JJ, Matthews D, Starko K, Francis DP, Maynard JE (1983) The effect of immunoglobulin on hepatitis A in day-care centers. JAMA, 249, 48-53.
3. Winokur PL, Stapleton JT (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis, 14, 580.
4. Flehmig B, Heinricy U, Pfister M (1989) Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet, i, 1039-1041.
5. Werzberger A, Mensch B, Kuter B et al. (1992) A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med, 327, 453-457.
6. Landry P, Tremblay S, Darioli R, Genton B (2000) Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine, 19, 399-402.
7. Iwarson S, Lindh M, Widerstrom L (2002) Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis, 34, 110-111.
8. Williams J, Bruden D, McMahon B et al. (2000) Response to two doses of hepatitis A vaccine administered an average of 27 months apart. Antiviral Ther, 13, 5.
9. Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K (2004) Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis, 23, 300-309.
10. ACIP (1999) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep, 48, 1-37.
11. Lopalco PL, Salleras L, Barbuti S et al. (2000) Hepatitis A and B in children and adolescents: what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine, 19, 470-474.
12. Salleras L, Bruguera M, Buti M, Domingez A (2000) Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Vaccine, 18 (Suppl), 80-82.
13. Chan CY, Lee SD, Yu MI et al. (1999) Long-term follow-up of hepatitis A vaccination in children. Vaccine, 17, 369-372.
14. Fan PC, Chang MH, Lee PI et al. (1998) Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine, 16, 232-235.
15. Van Damme P, Van Herck K (2002) Hepatitis A vaccination: more convenience for the traveller? Proceedings of the 3rd European Conference on Travel Medicine, Florence, 15-18 May, 2002. Rimini: World Health Organization Collaborating Centre for Travel Medicine, 50 (abstr 31).
16. Connor BA, Van Herck K, Van Damme P (2003) Rapid protection and vaccination against hepatitis A for travellers. BioDrugs, 17 (Suppl 1), 19-21.
17. Van Damme P, Mathei C, Thoelen S et al. (1994) Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol, 44, 435-441.
18. Briem H, Safary A (1994) Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol, 44, 443-445.
19. Van Herck K, Van Damme P (2001) Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol, 63, 1-7.
20. Werzberger A, Kuter B, Nalin D (1998) Six years' follow-up after hepatitis A vaccination. N Engl J Med, 338, 1160.
21. Wiens BL, Bohidar NR, Pigeon JG et al. (1996) Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol, 49, 235-241.
22. Werzberger A, Mensch B, Nalin DR, Kuter BJ (2002) Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' follow-up after the Monroe field trial of VAQTA. Vaccine, 20, 1699-1701.
23. Van Herck K, Renard D, Molenberghs G, Van Damme P (2002) Model-based estimates of long-term persistence of vaccine induced hepatitis A antibodies. In Dienstag J (ed.) Viral Hepatitis and Liver Diseases. Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Diseases, Atlanta, 9-13 April, 2000. Atlanta, GA: International Medical Press, 56-59.
24. Dagan R, Amir J, Mijalovsky A et al. (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J, 19, 1045-1052.
25. Piazza M, Safary A, Vegnente A et al. (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine, 17, 585-588.
26. Abarca K, Ibanez I, Flores J et al. (2001) Efficacy of hepatitis A vaccination in children aged 12 to 24 months. Arch Med Res, 32, 468-472.
27. Fiore AE, Shapiro CN, Sabin K et al. (2003) Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J, 22, 354-359.
28. Letson GW, Shapiro CN, Kuehn D et al. (2004) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr, 144, 327-332.
29. Van Herck K, Van Damme P, Lievens M, Stoffel M (2004) Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol, 72, 194-196.
30. Fiore AE, Shapiro C, Sabin KM, Labonte K, Bell BP, Margolis HS (2001) Persistence of protective antibody concentrations and response to a booster among children given hepatitis A vaccine during infancy: effect of maternal antibody. Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, 25-28 October, 2001. San Francisco, CA: Infectious Diseases Society of America, 378.
31. Van Damme P, Banatvala J, Fay O et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet, 362, 1065-1071.
32. Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest, 90, 2491-2495.
33. Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C (2003) Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine, 21, 4588-4592.
34. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol, 68, 489-493.
35. Beran J, Beutels M, Levie K et al. (2000) A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J Travel Med, 7, 246-252.
36. Sagliocca L, Amoroso P, Stroffilini T et al. (1999) Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet, 353, 1136-1139.
37. Flehmig B, Normann A, Bohnen D (2000) Transmission of hepatitis A virus infection despite vaccination. N Engl J Med, 343, 301-302.
38. Beasley RP, Hwang LY, Lin CC (1981) Hepatitis B immune globulin (HBIG) in the interruption of perinatal transmission of hepatitis B carrier state. Lancet, ii, 388-392.
39. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV (1995) Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med, 332, 1065-1069.
40. Confavreux C, Suissa A, Saddier P, Bourdes V, Vukusic S (2001) Vaccinations and the risk of relapse of multiple sclerosis. Vaccines in Multiple Sclerosis Group. N Engl J Med, 344, 319-326.
41. Ascherio A, Zhang SM, Hernan MA et al. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med, 344, 327-332.
42. American Academy of Pediatrics Committee on Infectious Diseases (2002) Recommended childhood immunization schedule-United States, 2002. Pediatrics, 109, 162-163.
43. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology, 1, 377-385.
44. Hadler SC, Francis DP, Maynard JE et al. (1986) Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med, 315, 209-214.
45. Koff RS (2002) Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine, 20, 3695-3701.
46. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H (1998) Immunogeniciry of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med, 15, 1-8.
47. West DJ, Calandra GB (1996) Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine, 14, 1019-1027.
48. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT (1993) Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA, 270, 2935-2939.
49. Alper CA, Kruskall MS, Marcus-Bagley D et al. (1989) Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med, 321, 708-712.
50. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL (1999) Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology, 29, 924-927.
51. Liao SS, Li RC, Li H et al. (1999) Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine, 17, 2661-2666.
52. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ (2003) Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J, 22, 157-163.
53. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS (2003) Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis, 187, 134-138.
54. Floreani A, Baldo V, Cristofoletti M et al. (2004) Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine, 22, 607-610.
55. European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet, 355, 561-565.
56. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K (1994) Persistence of immunological memory for twelve years in children given hepatitis B vaccination in infancy. Pediatr Infect Dis, 13, 745-747.
57. Whittle H, Jaffar S, Wansbrough M et al. (2002) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br Med J, 325, 569-573.
58. Carne CA, Weller IV, Waite J et al. (1987) Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J, 294, 866-868.
59. Stevens CE, Alter HJ (1984) Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy. N Engl J Med, 311, 496-501.
60. Chen DS, Sung JL (1978) Hepatitis B virus infection and chronic liver diseases in Taiwan. Acta Hepatogastroenterol, 25, 423-430.
61. Kao JH, Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis, 2, 395-403.
62. Ni YH, Chang MH, Huang LM et al. (2001) Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med, 135, 796-800.
63. Chen HL, Chang MH, Ni YH et al. (1996) Seroepidemiology of hepatitis B virus infection in children-ten years of mass vaccination in Taiwan. JAMA, 276, 906-908.
64. Lin HH, Wang LY, Hu CT et al. (2003) Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol, 69, 471-474.
65. Chang MH, Shau WY, Chen CJ et al. (2000) Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284, 3040-3042.
66. Kao JH, Chen DS (2002) Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. Int J Cancer, 97, 269-271.
67. Chen HL, Chang CJ, Kong MS et al. (2004) Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology, 39, 58-63.
68. Yang YJ, Liu CC, Chen TJ et al. (2003) Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J, 22, 584-588.
69. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G (2002) Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine, 20, 3739-3743.
70. Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G (2002) Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol, 67, 327-333.
71. Carman WF, Pagan EA, Hadziyannis S et al. (1991) Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology, 14, 219-222.
72. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S (1999) Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology, 29, 1252-1258.
73. Zuckerman JN, Zuckerman AJ, Symington I et al. (2001) Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology, 34, 798-802.
74. Zuckerman JN, Zuckerman AJ (2002) Recombinant hepatitis B triple antigen vaccine: Hepacare. Expert Rev Vaccines, 1, 141-144.
75. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ (2003) Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine, 21, 4604-4608.
76. Kim MJ, Nafziger AN, Harro CD et al. (2003) Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine, 21, 1174-1179.
77. Heineman TC, Clements-Mann ML, Poland GA et al. (1999) A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine, 17, 2769-2778.
78. Lewis DJ, Eiden JE, Goilav C, Langenberg AG, Suggett F, Griffin GE (2003) Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine. Commun Dis Public Health, 6, 320-324.
79. Jacques P, Moens G, Desombere I et al. (2002) The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine, 20, 3644-3649.
80. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 21, 2461-2467.
81. Van Damme P, Van der Wielen M (2001) Combining hepatitis A and B vaccination in children and adolescents. Vaccine, 19, 2407-2412.
82. Van Damme P, Leroux-Roels G, Law B et al. (2001) Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol, 65, 6-13.
83. Joines RW, Blatter M, Abraham B et al. (2001) A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine, 19, 4710-4719.
84. Kallinowski B, Knoll A, Lindner E et al. (2000) Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine, 19, 16-22.
85. Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. (1999) The first combined vaccine against hepatitis A and B: an overview. Vaccine, 17, 1657-1662.
86. Murdoch DL, Goa K, Figgitt DP (2003) Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs, 63, 2625-2649.
87. Jarvis B, Figgitt DP (2003) Combined two-dose hepatitis A and B vaccine (AmBirix). Drugs, 63, 207-213.
88. Carman WF, Zanetti AR, Karayiannis P et al. (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet, 336, 325-329.
89. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL (1999) Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination. Hepatology, 30, 1312-1317.
90. Clarke B (1997) Molecular virology of hepatitis C virus. J Gen Virol, 78, 2397-2410.
91. Bartenschlager R, Lohmann V (2000) Replication of hepatitis C virus. J Gen Virol, 81, 1631-1648.
92. Tokita H, Okamoto H, Iizuka H et al. (1998) The entire nucleotide sequences of three hepatitis C virus isolates in genetic groups 7-9 and comparison with those in the other eight genetic groups. J Gen Virol, 79, 1847-1857.
93. Gomez J, Martell M, Quer J, Cabot B, Esteban JI (1999) Hepatitis C viral quasispecies. J Viral Hepat, 6, 3-16.
94. Weiner AJ, Brauer MJ, Rosenblatt J et al. (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology, 180, 842-848.
95. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC (1998) Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology, 27, 223-227.
96. Chen M, Sallberg M, Sonnerborg A et al. (1999) Limited humoral immunity in hepatitis C virus infection. Gastroenterology, 116, 135-143.
97. Choo QL, Kuo G, Ralston R et al. (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA, 91, 1294-1298.
98. Farci P, Alter HJ, Wong DC et al. (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA, 91, 7792-7796.
99. Polakos NK, Drane D, Cox J et al. (2001) Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol, 166, 3589-3598.
100. Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ (2001) Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol, 75, 2130-2141.
101. Gruner N, Gerlach TJ, Jung MC et al. (2000) Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis, 181, 1528-1536.
102. Lagging LM, Meyer K, Hoft D et al. (1995) Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol, 69, 5859-5863.
103. Major ME, Vitviski L, Mink MA et al. (1995) DNA-based immunisation with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol, 69, 5798-5805.
104. Nakano I, Maertens G, Major ME et al. (1997) Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol, 71, 7101-7109.
105. Fournillier A, Nakano I, Vitvitski L et al. (1998) Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. Hepatology, 28, 237-244.
106. Brinster C, Muguet S, Lone YC et al. (2001) Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology, 34, 1206-1217.
107. Lazdina U, Hultgren C, Frelin L et al. (2001) Humoral and CD4 (+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol, 82, 1299-1308.
108. Encke J, zu Putlitz J, Geissler M, Wands JR (1998) Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol, 161, 4917-4923.
109. Pancholi P, Perkus M, Tricoche N, Liu Q, Prince AM (2003) DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol, 77, 382-390.
110. Cho JH, Lee SW, Sung YC (1999) Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine, 17, 1136-1144.
111. Duenas-Carrera S, Vina A, Martinez R et al. (2004) Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Macaca irus (crab-eating macaque monkeys). Biotechnol Appl Biochem, 39, 249-255.
112. Satoi J, Murata K, Lechmann M et al. (2001) Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol, 75, 12121-12127.
113. Inchauspe G (1999) DNA vaccine strategies for hepatitis C. J Hepatol, 30, 339-346.
114. Ma X, Forns X, Gutierrez R et al. (2002) DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine, 20, 3263-3271.
115. Encke J, zu Putlitz J, Stremmel W, Wands JR (2003) CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization. Arch Virol, 148, 435-448.
116. Fournillier A, Wychowski C, Boucreux D et al. (2001) Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol, 75, 12088-12097.
117. Youn JW, Park SH, Cho JH, Sung YC (2003) Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. J Virol, 77, 11596-11602.
118. Jiao X, Wang RY, Feng Z, Alter HJ, Shih JW (2003) Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology, 37, 452-460.
119. Ha SJ, Chang J, Song MK et al. (2002) Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat Biotechnol, 20, 381-386.
120. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC (2004) IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol, 172, 525-531.
121. Frelin L, Alheirn M, Chen A et al. (2003) Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther, 10, 686-699.
122. Fournilier A, Depla E, Karayiannis P et al. (1999) Expression of non-covalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralising properties following DNA immunisation. J Virol, 73, 7497-7504.
123. Forns X, Payette PJ, Ma X et al. (2000) Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology, 32, 618-625.
124. Rollier C, Depla E, Drexhage JA et al. (2004) Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol, 78, 187-196.
125. Makimura M, Miyake S, Akino N et al. (1996) Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine, 14, 28-36.
126. Arribillaga L, de Cerio AL, Sarobe P et al. (2002) Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine, 21, 202-210.
127. Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T (2002) Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine, 21, 211-220.
128. Brinster C, Chen M, Boucreux D et al. (2002) Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol, 83, 369-381.
129. Buonocore L, Blight KJ, Rice CM, Rose JK (2002) Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol, 76, 6865-6872.
130. Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus ME, Prince AM (2000) DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis, 182, 18-27.
131. Matsui M, Moriya O, Akatsuka T (2003) Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine, 21, 1629-1639.
132. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B (2001) Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology, 121, 1158-1166.
133. Uno-Furuta S, Matsuo K, Tamaki S et al. (2003) Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine, 21, 3149-3156.
134. Simon BE, Cornell KA, Clark TR, Chou S, Rosen HR, Barry RA (2003) DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun, 71, 6372-6380.
135. Zucchelli S, Roccasecca R, Meola A et al. (2001) Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. Hepatology, 33, 692-703.
136. Lechmann M, Murata K, Satoi J et al. (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology, 34, 417-423.
137. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA, 100, 6753-6758.
138. Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ (2003) Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology, 37, 52-59.
139. Sarobe P, Lasarte JJ, Zabaleta A et al. (2003) Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol, 77, 10862-10871.
140. Racanelli V, Behrens SE, Aliberti J, Rehermann B (2004) Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity, 20, 47-58.
141. Karayiannis P (1998) Hepatitis D virus. Rev Med Virol, 8, 13-24.
142. Monjardino J, Lai MMC (1998) Hepatitis D virus: structure and molecular biology. In Zuckerman AJ, Thomas HC (eds) Viral Hepatitis (2nd edn). London: Churchill Livingstone, 359-369.
143. Karayiannis P, Saldanha J, Monjardino J et al. (1990) Immunisation of woodchucks with recombinant delta antigen does not protect against delta virus infection. Hepatology, 12, 1125-1128.
144. Karayiannis P, Saldanha J, Jackson AM et al. (1993) Control of hepatitis delta virus super-infection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol, 41, 210-214.
145. Huang YH, Wu JC, Tao MH et al. (2000) DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology, 32, 104-110.
146. Huang YH, Wu JC, Hsu SC, Syu WJ (2003) Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. J Virol, 77, 12980-12985.
147. Fiedler M, Lu M, Siegel F, Whipple J, Roggendorf M (2001) Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine, 19, 4618-4626.
148. Yarbough PO (1999) Hepatitis E virus. Advances in HEV biology and HEV vaccine approaches. Intervirology, 42, 179-184.
149. Yarbough PO (1998) Hepatitis E virus: diagnosis. In Zuckerman AJ, Thomas HC (eds) Viral Hepatitis (2nd edn). London: Churchill Livingstone, 411-416.
150. Meng XJ (2000) Novel strains of hepatitis E virus identified from humans and other animal species: is hepatitis E a zoonosis? J Hepatol, 33, 842-845.
151. Purdy MA, McCaustland KA, Krawczynski K et al. (1993) Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol, 41, 90-94.
152. Tsarev SA, Tsareva TS, Emerson S et al. (1994) Infectivity titration of a prototype strain of hepatitis E virus in cynomolgus monkeys. J Med Virol, 43, 135-142.
153. Tsarev SA, Tsareva TS, Emerson SU et al. (1994) Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci USA, 91, 10198-10202.
154. Fuerst TR, Yarbough PO, Zhang Y et al. (1996) Prevention of hepatitis E using a novel ORF-2 subunit vaccine. In Buisson Y, Coursaget P, Kane M (eds) Enterically-transmitted Hepatitis Viruses. Joué-les-Tours: La Simarre, 384-392.
155. Tsarev SA, Tsareva TS, Emerson SU et al. (1997) Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine, 15, 1834-1838.
156. Lu F, Zhuang H, Zhu Y, Zhu X (1996) A preliminary study on immune response to hepatitis E virus DNA vaccine in mice. Chin Med J, 109, 919-921.
157. Zhang M, Emerson SU, Nguyen H et al. (2001) Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells. Vaccine, 20, 853-857.
158. Purcell RH, Nguyen H, Shapiro M et al. (2003) Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine, 21, 2607-2615.
159. Im SWK, Zhang JZ, Zhuang H et al. (2001) A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus. Vaccine, 19, 3726-3732.
160. He J, Hoffman SL, Hayes CG (1997) DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine, 15, 357-362.
161. Li F, Riddell MA, Seow HF, Takeda N, Miyamura T, Anderson DA (2000) Recombinant subunit ORF2.1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein. J Med Virol, 60, 379-386.
162. Che XY, Qian QJ, Liu SX et al. (2002) Construction of specifically targeted chimeric hepatitis E virus DNA vaccine and its efficacy assessment. Di Yi Jun Yi Da Xue Xue Bao, 22, 97-101.
163. Tuteja R, Li TC, Takeda N, Jameel S (2000) Augmentation of immune responses to hepatitis E virus ORF2 DNA vaccination by codelivery of cytokine genes. Viral Immunol, 13, 169-178.
164. Kamili S, Spelbring J, Carson D, Krawczynski K (2004) Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. J Infect Dis, 189, 258-264.